Fondo Bibliografico Internacional Noviembre 2003
Trasplante hepático.
Hepatitis C virus therapy, hepatocyte drug metabolism,
and risk for acute cellular rejection. Kugelmas M, Osgood MJ, Trotter JF,
Bak T, Wachs M, Forman L, Kam I, Everson GT. Liver Transplantation 2003;9:1159-1165.
Los niveles de inmunosupresores disminuyen
más en los pacientes que respondieron al tratamiento antiviral.
Delayed onset of severe hepatitis C-related liver damage following
liver transplantation: a matter of concern? Berenguer M, Aguilera V, Prieto
M, Carrasco D, Rayon M, San Juan F, Landaverde C, Mir J, Berenguer J. Liver
Transplantation 2003;9:1152-1158.
Una tercera parte de los pacientes tienen lesiones
hepáticas graves a largo plazo, a pesar de una recurrencia de la infección
inicialmente poco importante.
Liver transplantation: what do we really know about the long-term
impact? Moore KA. Liver Transplantation 2003;9:1149-1151.
Editorial
Cognitive dysfunction and health-related quality of life in
long-term liver transplant survivors. Lewis MB, Howdle PD. Liver Transplantation
2003;9:1145-1148.
Los pacientes trasplantados que sobreviven más
de 10 años tienen una pobre calidad de vida.
Controversies in the management of hepatitis C virus infection
after liver transplantation. Shiffman ML, Vargas HE, Everson GT. Liver Transplantation
2003;9:1129-1144
Revisión.
New approaches and therapeutic modalities for the prevention
and treatment of recurrent HCV after liver transplantation. Davis GL. Liver
transplantation 2003; 9:S114-9.
Revisión.
How can we identify better those with recurrent hepatitis
C who will respond to therapy? What are the optimal treatment regimen and
treatment duration? Wright TL. Liver transplantation 2003; 9:S109-13.
Revisión.
Treatment of hepatitis C virus infection in the allograft.
Neuberger J. Liver transplantation 2003; 9:S101-8.
Revisión.
Treatment of patients with hepatitis C virus on the waiting
list. Everson GT. Liver transplantation 2003; 9:S90-4.
Revisión.
The clinical and immunologic impact of using interferon and
ribavirin in the immunosuppressed host. Braun M, Vierling JM. Liver transplantation
2003; 9:S79-89.
Revisión.
Retransplantation for recurrent hepatitis C: The argument
against. Wall WJ, Khakhar A. Liver transplantation 2003; 9:S73-8.
Revisión.
Retransplantation for recurrent hepatitis C: Positive aspects.
McCashland TM. Liver transplantation 2003; 9:S67-72.
Revisión.
The role of immunosuppression in recurrence of hepatitis C.
Lake JR. Liver transplantation. 2003 9:S63-6.
Revisión.
Liver biopsy, viral kinetics, and the impact of viremia on
severity of hepatitis C virus recurrence. Charlton M. Liver transplantation
2003; 9:S58-62.
Revisión.
Living donor liver transplantation in patients with hepatitis
C. Zimmerman MA, Trotter JF. Liver transplantation 2003; 9:S52-7.
Revisión.
The use of hepatitis C-infected grafts in liver transplantation.
Arenas JI, Vargas HE, Rakela J. Liver transplantation 2003; 9:S48-51.
Revisión.
Host and donor risk factors before and after liver transplantation
that impact HCV recurrence. Berenguer M. Liver transplantation 2003; 9:S44-7.
Revisión.
Hepatitis C pathogenesis: Mechanisms of viral clearance and
liver injury. Rosen HR. Liver transplantation 2003; 9:S35-43.
Revisión.
The natural history and outcome of liver transplantation in
hepatitis C virus-infected recipients. Gane E. Liver transplantation 2003;
9:S28-34.
Revisión.
Impact of immunosuppression on immunopathogenesis of liver
damage in hepatitis C virus-infected recipients following liver transplantation.
McCaughan GW, Zekry A. Liver transplantation 2003; 9:S21-7.
Revisión.
Natural history and risk factors for progression of hepatitis
C virus disease and development of hepatocellular cancer before liver transplantation.
Shiffman ML. Liver Transplantation 2003; 9:S14-20.
Revisión.
Scope of worldwide hepatitis C problem. Brown RS Jr, Gaglio
PJ. Liver transplantation 2003; 9:S10-3.
Revisión.
Report of the first international liver transplantation society
expert panel consensus conference on liver transplantation and hepatitis C.
Wiesner RH, Sorrell M, Villamil F. Liver transplantation 2003; 9:S1-9.
Liver transplantation for growing teratoma syndrome: Report
of a case. Eghtesad B, Marsh WJ, Cacciarelli T, Geller D, Reyes J, Jain A,
Fontes P, Devera M, Fung J. Liver transplantation 2003; 9:1222-4.
Caso clínico.
Immunosuppressive therapy in liver transplantation. Conti
F, Morelon E, Calmus Y. Journal of Hepatology 2003; 39:664-78.
Revisión.
Liver transplantation for growing teratoma syndrome: report
of a case. Eghtesad B, Marsh WJ, Cacciarelli T, Geller D, Reyes J, Jain A,
Fontes P, Devera M, Fung J. Liver Transplantation 2003;9:1222-1224.
Caso clínico.
Oxygen availability during orthotopic liver transplantation.
Kostopanagiotou G, Smyrniotis V, Theodoraki K, Skalkidis Y, Heaton N, Potter
D. Liver Transplantation 2003;9:1216-1221.
La determinación del P50 puede ser útil
para evaluar la oxigenación sistémica durante el trasplante
hepático.
The sickest first? Disparities with model for end-stage liver
disease-based organ allocation: one region's experience. Schaffer RL 3rd,
Kulkarni S, Harper A, Millis JM, Cronin DC 2nd. Liver Transplantation 2003;9:1211-1215.
Impacto del sistema MELD para la distribución
de órganos procedentes de cadáver.
Are preformed antibodies to biliary epithelial cells of clinical
importance in liver transplantation? Ge X, Ericzon BG, Nowak G, oHrstrom H,
Broome U, Sumitran-Holgersson S. Liver Transplantation 2003;9:1191-1198.
La mayor incidencia de anticuerpos frente al epitelio
biliar se asocial a una mayor tasa de rechazo agudo.
Live donor liver transplantation for fulminant hepatic failure
in children. Liu CL, Fan ST, Lo CM, Tam PK, Saing H, Wei WI, Yong BH, Tsoi
NS, Wong J. Liver Transplantation 2003;9:1185-1190.
Experiencia sobre ocho niños con hepatitis
fulminate que se trasplantan con donante vivo.
Living donor liver transplantation for hepatitis B cirrhosis.
Sugawara Y, Makuuchi M, Kaneko J, Akamatsu N, Imamura H, Kokudo N. Liver Transplantation
2003;9:1181-1184.
Buenos resultados de este tipo de trasplante en relación
a la supervivencia.
Long-term survival of recipients of liver grafts from donors
older than 80 years: is it achievable? Cescon M, Grazi GL, Ercolani G, Nardo
B, Ravaioli M, Gardini A, Cavallari A. Liver Transplantation 2003;9:1174-1180.
Buenos resultados del trasplante de hígado
procedente de donantes viejos, aunque con una elevada tasa y rapidez de reinfeción
por el VHC.
Estimating the number of potential organ donors in the United
States. Tuppin P, Pessione F. New England Journal of Medicine 2003; 349:2073-5.
Carta.
Estimating the number of potential organ donors in the
United States. Spital A. New England Journal of Medicine 2003; 349:2073-5.
Carta.
